Dr. Toru Miyazaki, who discovered the AIM protein and uncovered its role in feline CKD, is currently conducting a blood test survey aimed at understanding the prevalence and stages of CKD in cats across different regions in Japan. Initially seeking 500 applicants, the survey has already received 550 applications, surpassing expectations, and remains ongoing. Eligible applicants must be cats who are at least 10 years old and have been diagnosed with CKD in the past.
To facilitate blood collection, Dr. Miyazaki has released a list of participating veterinary hospitals in Japan, primarily those that have previously collaborated on AIM research. This list will continue to expand as more facilities join the initiative. As of now, 35% of the 550 applicants have completed the blood test process.
Meanwhile, Dr. Miyazaki's AIM drug for cats has completed development, and clinical trials are scheduled to begin and conclude within the year, with official approval applications planned for next year.
Dr. Miyazaki’s groundbreaking research not only drives the development of AIM-based treatments but also informs Greycoat Research’s approach to feline CKD management. His expertise provides the foundation for the Dr. Toru Protocol, an AIM-based supplement designed to support kidney health based on his findings. In addition, Dr. Miyazaki provides expert guidance to Greycoat Research, ensuring that cat owners who use Greycoat’s free consultation services receive the latest, research-backed advice on CKD care.
As AIM-based treatments progress toward clinical application, Greycoat Research continues its mission to provide data-driven CKD management solutions to cat owners worldwide.
